Physician profile
Seth Leven
NPI 1588805840
$2,323.94
in general payments reported to CMS, 2019-2025
26 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $16.19 · 2022: $185 · 2023: $824 · 2024: $639 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,123.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $338.85 | 2022-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $308.57 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $299.68 | 2023-2025 | Breztri, Farxiga, Fasenra |
| Novo Nordisk INC | $271.12 | 2023-2025 | Wegovy, Ozempic, Saxenda |
| Lilly USA, LLC | $147.14 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Exact Sciences Corporation | $121.93 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $114.78 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.20 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $106.96 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $58.00 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.35 | 2024 | Xifaxan |
| Sanofi Pasteur INC. | $40.13 | 2022-2023 | |
| Abbott Laboratories | $39.27 | 2025 | Freestyle Libre |
| Idorsia Pharmaceuticals US INC | $36.96 | 2023 | Quviviq |
| Celgene Corporation | $35.20 | 2023 | Camzyos |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $33.98 | 2025 | Dupixent |
| Sumitomo Pharma America, INC. | $29.21 | 2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $26.61 | 2023 | |
| Corium, LLC | $25.13 | 2023 | Azstarys |
| Dexcom, INC. | $24.44 | 2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $22.38 | 2023 | Mycapssa |
| Eisai INC. | $21.94 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.30 | 2024 | Trintellix |
| Allergan, INC. | $16.19 | 2020 | |
| Merck Sharp & Dohme LLC | $15.50 | 2023 | Belsomra, Steglatro |
| Currax Pharmaceuticals LLC | $15.12 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seth Leven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.